148 related articles for article (PubMed ID: 30662312)
1.
Shariare MH; Altamimi MA; Marzan AL; Tabassum R; Jahan B; Reza HM; Rahman M; Ahsan GU; Kazi M
Saudi Pharm J; 2019 Jan; 27(1):96-105. PubMed ID: 30662312
[TBL] [Abstract][Full Text] [Related]
2. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
[TBL] [Abstract][Full Text] [Related]
3. Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability.
Thadkala K; Nanam PK; Rambabu B; Sailu C; Aukunuru J
Int J Pharm Investig; 2014 Jul; 4(3):131-7. PubMed ID: 25126526
[TBL] [Abstract][Full Text] [Related]
4. Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability.
Parmar K; Shah J
Curr Drug Deliv; 2021; 18(8):1148-1161. PubMed ID: 33438540
[TBL] [Abstract][Full Text] [Related]
5. Development of a Resveratrol Nanosuspension Using the Antisolvent Precipitation Method without Solvent Removal, Based on a Quality by Design (QbD) Approach.
Kuk DH; Ha ES; Ha DH; Sim WY; Lee SK; Jeong JS; Kim JS; Baek IH; Park H; Choi DH; Yoo JW; Jeong SH; Hwang SJ; Kim MS
Pharmaceutics; 2019 Dec; 11(12):. PubMed ID: 31861173
[TBL] [Abstract][Full Text] [Related]
6. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
7. Study of Formulation and Process Variables for Optimization of Piroxicam Nanosuspension Using 3
Alhamhoom Y; Honmane SM; Hani U; Osmani RAM; Kandasamy G; Vasudevan R; Paramshetti S; R Dudhal R; K Kengar N; Charde MS
Polymers (Basel); 2023 Jan; 15(3):. PubMed ID: 36771784
[TBL] [Abstract][Full Text] [Related]
8. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
[TBL] [Abstract][Full Text] [Related]
9. 24 Factorial Design Formulation Optimization and In vitro Characterization of Desloratadine Nanosuspension Prepared Using Antisolvent Precipitation.
El-Sebaiy MT; Alyami MH; Alyami HS; Kamal MA; Eissa N; Balata G; El-Nahas H
Curr Drug Deliv; 2024 Jun; ():. PubMed ID: 38867526
[TBL] [Abstract][Full Text] [Related]
10. Comparative study on stabilizing ability of food protein, non-ionic surfactant and anionic surfactant on BCS type II drug carvedilol loaded nanosuspension: Physicochemical and pharmacokinetic investigation.
Geng T; Banerjee P; Lu Z; Zoghbi A; Li T; Wang B
Eur J Pharm Sci; 2017 Nov; 109():200-208. PubMed ID: 28811130
[TBL] [Abstract][Full Text] [Related]
11. Nanoprecipitation with sonication for enhancement of oral bioavailability of furosemide.
Sahu BP; Das MK
Acta Pol Pharm; 2014; 71(1):129-37. PubMed ID: 24779201
[TBL] [Abstract][Full Text] [Related]
12. Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box-Behnken Design Optimization.
Boscolo O; Flor S; Salvo L; Dobrecky C; Höcht C; Tripodi V; Moretton M; Lucangioli S
Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631251
[TBL] [Abstract][Full Text] [Related]
13. Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique.
Zu Y; Wu W; Zhao X; Li Y; Wang W; Zhong C; Zhang Y; Zhao X
Int J Pharm; 2014 Aug; 471(1-2):366-76. PubMed ID: 24882039
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.
Thakkar HP; Patel BV; Thakkar SP
J Pharm Bioallied Sci; 2011 Jul; 3(3):426-34. PubMed ID: 21966165
[TBL] [Abstract][Full Text] [Related]
15. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
16. Quality by design-based optimization of formulation and process parameters for berberine nanosuspension for enhancing its dissolution rate, bioavailability, and cardioprotective activity.
Alsabeelah N; Kumar V
J Food Biochem; 2022 Oct; 46(10):e14361. PubMed ID: 35929374
[TBL] [Abstract][Full Text] [Related]
17. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
Karakucuk A; Celebi N; Teksin ZS
Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
[TBL] [Abstract][Full Text] [Related]
18. Preparation and Characterization of Nanosuspension of Aprepitant by H96 Process.
Kalvakuntla S; Deshpande M; Attari Z; Kunnatur B K
Adv Pharm Bull; 2016 Mar; 6(1):83-90. PubMed ID: 27123422
[TBL] [Abstract][Full Text] [Related]
19. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
20. Increase in Dissolution Rate of Zotepine via Nanomilling Process - Impact of Dried Nanocrystalline Suspensions on Bioavailability.
Parmar K; Oza K
AAPS PharmSciTech; 2021 Dec; 23(1):20. PubMed ID: 34907489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]